Loading...
OTCM
SHTDY
Market cap6.64bUSD
Jul 09, Last price  
10.68USD
1D
-1.84%
1Q
-19.64%
Jan 2017
-47.90%
IPO
-50.60%
Name

Sinopharm Group Co Ltd

Chart & Performance

D1W1MN
OTCM:SHTDY chart
P/E
31.60
P/S
0.39
EPS
2.29
Div Yield, %
5.63%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
4.73%
Revenues
575.17b
-1.60%
23,736,642,00031,110,214,00038,187,433,00047,045,853,00069,233,669,000102,224,807,000135,786,836,000166,866,146,000200,131,261,000228,672,929,000258,117,225,000277,028,977,000344,525,821,000425,272,726,000456,414,611,000521,051,235,000552,147,550,000596,569,565,000584,507,930,000575,167,877,000
Net income
7.16b
+1.50%
182,448,000535,949,000818,103,000845,819,0001,208,751,0001,560,606,0001,973,823,0002,250,002,0002,874,823,0003,760,649,0004,647,344,0007,868,176,0009,404,484,00010,620,072,0007,187,278,0007,758,646,0008,525,655,0009,053,760,0007,049,683,0007,155,094,000
CFO
14.14b
+22.45%
638,439,000441,180,000653,849,0001,011,505,0001,202,537,0001,019,269,0004,017,209,0004,941,294,0005,560,835,00013,412,333,0009,257,964,0001,667,345,0003,653,739,00018,777,096,00011,154,609,0009,308,085,00020,963,787,00017,173,030,00011,546,015,00014,138,206,000
Dividend
Jun 18, 20240.601 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products. The company organizes its extensive operations across four distinct divisions. Its Pharmaceutical Distribution unit supplies a wide array of medicinal products to various clients, including hospitals, other distributors, retail pharmacies, and clinics. This segment also provides comprehensive distribution, logistics, and additional value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers. The Medical Devices segment is dedicated to the distribution of medical equipment. Through its Retail Pharmacy division, the company oversees and franchises a substantial network of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies. Beyond these core areas, the company's activities extend to property leasing and management; the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products; information technology development; a variety of consulting services (medicine, health, business, market information); investment management; import and export; and convention and exhibition services. Additionally, it manages medical project investments, consulting, and technology training initiatives. Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab to enhance its commercial reach and market transformation efforts. The company was established in 2003, with its headquarters located in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
IPO date
Sep 23, 2009
Employees
113,362
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT